Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05646719 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia
A Phase 3 study, sponsored by Ocuphire Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 333
- Enrollment target
NCT05646719 is a Phase 3 study that has completed, run by Ocuphire Pharma. The registered enrollment target is 333 participants.
The verdict
NCT05646719, a Phase 3 study, has completed, sponsored by Ocuphire Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 333 participants
- Enrollment target
Study Summary
The objectives of this study are: To evaluate the safety and efficacy of Nyxol alone and with adjunctive low dose pilocarpine to improve distance-corrected near visual acuity (DCNVA) in subjects with presbyopia.
Interventions
- OTHER Placebo
- DRUG Phentolamine Opthalmic Solution 0.75%
- DRUG Low dose pilocarpine
- OTHER Low dose pilocarpine vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 333 participants |
| Start Date | 2022-12-22 |
| Est. Completion | 2023-10-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05646719
The ClinicalTrials.gov registry entry for NCT05646719 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 333 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocuphire Pharma, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT05646719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05646719 about?
NCT05646719 is a clinical study titled "Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia". The objectives of this study are: To evaluate the safety and efficacy of Nyxol alone and with adjunctive low dose pilocarpine to improve distance-corrected near visual acuity (DCNVA) in subjects with presbyopia.
What is the current status of trial NCT05646719?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 333 participants. The study started on 2022-12-22. Estimated completion is 2023-10-11.
What interventions are being tested in trial NCT05646719?
The interventions under investigation include: Placebo (OTHER), Phentolamine Opthalmic Solution 0.75% (DRUG), Low dose pilocarpine (DRUG), Low dose pilocarpine vehicle (OTHER).
Who is sponsoring clinical trial NCT05646719?
This trial is sponsored by Ocuphire Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.